Categories LATEST, Technology

Nutanix stock gets a breather on bullish analyst comment

Cloud computing software company Nutanix (NASDAQ: NTNX) got a breather on Thursday on bullish comments from an analyst, after months of declining stock price. The stock opened 6.4% in green on Thursday after trading higher during pre-market hours.  

Jason Ader of William Blair said in a research note that he believes the stock could be on the verge of an upswing.

nutanix
Image by Wynn Pointaux from Pixabay

“According to multiple VARs (value-added resellers), the pipeline expansion has been supported by aggressive sales hiring at Nutanix and increasing sales coverage,” he said, adding their July business saw a higher number of seven-figure deals.

Adler has an Outperform rating on the stock.

Meanwhile, Jonathan Ruykhaver of Robert. W Baird set a price target of $41 on the stock, which is at a 48% upside from the current trading price. He maintains a Buy rating on NTNX. On the whole, 10 out of 16 analysts covering the stock has a Buy rating, with the 12-month average price target at $38.

READ: Microsoft leads the enterprise SaaS industry, grows quickly

In the trailing 12 months, Nutanix stock has declined almost 50% of its value, even as the iShares Expanded Tech-Software (IGV) gained 18.8%.

In May, Nutanix reported third-quarter revenue that fell short of both analysts’ and the company’s predictions, sending its stock plunging 15%. The hybrid cloud infrastructure company also provided outlook, which came below the street expectations.

nutanix Q3 2019 earnings infographic

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top